McKesson Corporation· MCK

McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson NYSE: MCK discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter.

Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural Upside

McKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. The oncology segment is driving growth, with a 31% YoY revenue increase and strategic acquisitions reinforcing the shift toward higher-margin businesses. Despite negative shareholder equity from buybacks and opioid liabilities, MCK maintains strong liquidity, low leverage, and disciplined capital returns.

McKesson Corporation $MCK Shares Acquired by Barlow Wealth Partners LLC

Barlow Wealth Partners LLC lifted its position in shares of McKesson Corporation (NYSE: MCK) by 96.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,820 shares of the company's stock after purchasing an additional 16,596 shares during the

Here's Why McKesson (MCK) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

RBC Capital Starts McKesson (MCK) at Sector Perform

McKesson price target raised to $1,000 from $925 at Barclays

McKesson (MCK) PT Raised to $933 at Wells Fargo

McKesson price target raised to $1,050 from $1,000 at UBS

McKesson price target lowered to $875 from $973 at Deutsche Bank